These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24077553)

  • 21. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuated heart rate response in REM sleep behavior disorder and Parkinson's disease.
    Sorensen GL; Kempfner J; Zoetmulder M; Sorensen HB; Jennum P
    Mov Disord; 2012 Jun; 27(7):888-94. PubMed ID: 22555939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autonomic function assessment in Parkinson's disease patients using the kernel method and entrainment techniques.
    Kamal AK
    Biomed Sci Instrum; 2007; 43():140-5. PubMed ID: 17487071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Autonomic nervous system dysfunction in Parkinson's disease evaluated by the heart rhythm variability test].
    Krygowska-Wajs A; Grabowska-Maślanka H; Tabor S; Sobocki J; Szczudlik A; Thor P
    Folia Med Cracov; 1997; 38(3-4):47-52. PubMed ID: 10481381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circadian heart rate variability in Parkinson's disease.
    Pursiainen V; Haapaniemi TH; Korpelainen JT; Huikuri HV; Sotaniemi KA; Myllylä VV
    J Neurol; 2002 Nov; 249(11):1535-40. PubMed ID: 12420094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced sympathetically driven heart rate variability during sleep in Parkinson's disease: a case-control polysomnography-based study.
    Sauvageot N; Vaillant M; Diederich NJ
    Mov Disord; 2011 Feb; 26(2):234-40. PubMed ID: 21284038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiration and heart rate variability during sleep in untreated Parkinson patients.
    Ferini-Strambi L; Franceschi M; Pinto P; Zucconi M; Smirne S
    Gerontology; 1992; 38(1-2):92-8. PubMed ID: 1612468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart rate variability and Parkinson's disease severity.
    Devos D; Kroumova M; Bordet R; Vodougnon H; Guieu JD; Libersa C; Destee A
    J Neural Transm (Vienna); 2003 Sep; 110(9):997-1011. PubMed ID: 12928836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional connectivity between lateral premotor-parietal circuits and the cardiac autonomic system in Parkinson's disease.
    Liou LM; Ruge D; Chang YP; Wu MN; Hsu CY; Lin CW; Tsai CL; Lai CL
    J Neurol Sci; 2013 Mar; 326(1-2):48-52. PubMed ID: 23375958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Side-effects of L-dopa on venous tone in Parkinson's disease: a leg-weighing assessment.
    Wolf JP; Bouhaddi M; Louisy F; Mikehiev A; Mourot L; Cappelle S; Vuillier F; Andre P; Rumbach L; Regnard J
    Clin Sci (Lond); 2006 Mar; 110(3):369-77. PubMed ID: 16302846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy.
    Pilleri M; Levedianos G; Weis L; Gasparoli E; Facchini S; Biundo R; Formento-Dojot P; Antonini A
    Parkinsonism Relat Disord; 2014 Feb; 20(2):217-21. PubMed ID: 24290883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of N-type Ca2+ channels ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure.
    Yamada Y; Kinoshita H; Kuwahara K; Nakagawa Y; Kuwabara Y; Minami T; Yamada C; Shibata J; Nakao K; Cho K; Arai Y; Yasuno S; Nishikimi T; Ueshima K; Kamakura S; Nishida M; Kiyonaka S; Mori Y; Kimura T; Kangawa K; Nakao K
    Cardiovasc Res; 2014 Oct; 104(1):183-93. PubMed ID: 25100767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Measurements of heart rate variability and baroreflex sensitivity].
    Sevre K; Rostrup M
    Tidsskr Nor Laegeforen; 2001 Oct; 121(26):3059-64. PubMed ID: 11757441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
    Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
    Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diurnal variability of heart rate in paroxysmal ventricular tachycardia: discovery of real clinical importance or only electrocardiographic feature?].
    Giec L
    Kardiol Pol; 1992 Nov; 37(11):291-2. PubMed ID: 1287290
    [No Abstract]   [Full Text] [Related]  

  • 40. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.